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Abstract
Introduction: Pulmonary Rehabilitation (PR) is an effective intervention in COPD however the value of PR in
reducing cardiovascular risk in COPD (measured by aortic pulse wave velocity, aPWV) is unclear and there is no
existing systematic review.
Objectives: To conduct a systematic review examining whether PR results in alteration of CV risk in COPD (as measured
by aPWV).
Methods: An electronic systematic search concordant with PRISMA guidelines was conducted. The search was complete
to the 27th of May 2017. Six databases were examined: Embase, Medline, AMED, Web of Science, Cochrane clinical trials,
and CINAHL.
Results: This study generated 767 initial matches, which were filtered using inclusion/exclusion criteria. Three
studies (201 COPD participants) were included. Our analysis does not confirm that PR affects aPWV but studies
were heterogeneous.
Conclusion: There is currently insufficient information on the effect of PR on reducing CV risk in COPD. Therefore
controversy remains, with the possibility that there might be some subjects who benefit and others who might
experience an increase in CV risk in response to PR. These results will be of value to those interested in gaining a
better understanding of the benefits of PR on CV risk in COPD.
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Introduction
According to the World Health Organisation (WHO)
[1], chronic obstructive pulmonary disease (COPD) is a
leading cause of death. In part, the elevated mortality in
COPD derives from an enhanced risk of cardiovascular
disease (CVD) [2]. Without mitigation, COPD will be
the third most common cause of death by 2030 [1].
COPD is defined as “a common, preventable and treat-
able disease that is characterized by persistent respira-
tory symptoms and airflow limitation that is due to
airway and/or alveolar abnormalities usually caused by
significant exposure to noxious particles or gases” [3].
Arterial stiffness is a gold-standard predictor of individual
cardiovascular risk [4], and a biomarker of elevated car-
diovascular risk in COPD patients [5], as it is in healthy
populations. It can be measured using aortic pulse wave
velocity [6]. It is known that COPD patients have in-
creased arterial stiffness compared to controls [7, 8], and
we have previously reported a relationship between the
frequency of exacerbation and arterial stiffness [9].
Interventions to reduce cardiovascular risk in COPD
patients are therefore of profound importance, yet existing
evidence is not consistent and requires further investiga-
tion. Pulmonary Rehabilitation (PR) – a group exercise
and education programme - is an evidence-based effective
intervention in COPD to reduce symptoms, improve exer-
cise performance and prevent exacerbations [10]. PR is de-
fined by the European Respiratory Society (ERS) and
American Thoracic Society (ATS) as “an evidence-based,
multidisciplinary, and comprehensive intervention for pa-
tients with chronic respiratory diseases who are symptom-
atic and often have decreased daily life activities” [11].
Whilst exercise may reduce cardiovascular risk, the effect
of exercise training and/or PR programme on cardiovas-
cular risk in COPD remains controversial. The objective
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of this systematic review was to summarise and report the




This systematic review is concordant with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [12]. The search was
complete to the 27th of May 2017. The search was per-
formed using six electronic databases (Excerpta Medica
dataBASE (Embase), MEDLARS Online (Medline), Allied
and Complementary Medicine Database (AMED), Web of
Science database, Cochrane clinical trials database, and
Cumulative Index of Nursing and Allied Health Literature
(CINAHL)).
All relevant titles and abstracts were read to evaluate
eligibility based on our inclusion criteria. After reading
the full texts, the first author eliminated non-relevant ar-
ticles where potentially relevant articles were reviewed
by the other authors to confirm eligibility.
Inclusion and exclusion criteria
The included studies met the following criteria:
1) Studies of patients with spirometrically-confirmed
COPD.
2) Patients enrolled on a PR or an exercise training
program.
3) Patients had cardiovascular risk assessment
measured using aPWV before and after the
programme to assess change in CV risk.
We excluded books, systematic reviews, non-English
manuscripts, conference abstracts with no full-text and
non-full text articles.
The primary outcome was change in cardiovascular
risk measured using arterial stiffness in response to pul-
monary rehabilitation or an exercise-training programme.
Results
Our search strategy (available in the Additional file 1),
identified 767 articles, and one additional article was
identified by screening reference lists. Of these, only three
met all our inclusion and exclusion criteria (Fig. 1). Of the
three included studies, two investigated COPD patients
who had been enrolled on a PR programme, and one re-
ported outcomes from patients enrolled on an exercise
endurance training programme. In summary, with re-
gard to the effect of PR on CV risk in COPD, we found
one larger negative study [7] and two smaller positive
studies [5, 6].
A detailed description of the three studies is given in
Table 1. The sample size and duration of the included
studies varied: 4 weeks, 7 weeks and two years. The sample
size ranged from 17 to 330 participants.
Quality assessment
Among the three included studies, two were cohort
studies and one was a randomized clinical trial. To as-
sess the quality and the risk of bias of each article, the
Newcastle-Ottawa scale (modified) [13] was used for co-
hort studies as indicated in Table 2 and the Cochrane
risk of bias tool (modified) [14] was used for the rando-
mised clinical trial as indicated in Table 3.
Discussion
This systematic review was conducted to evaluate the ef-
fects of exercise and/or pulmonary rehabilitation (PR) on
cardiovascular risk in COPD as assessed by arterial stiff-
ness. As reported in Table 1, there is one (larger) negative,
and two (smaller) positive studies. Controversy remains
over the effects of PR on cardiovascular risk. Studies were
too heterogeneous to permit meta-analysis. This is the
first systematic review to address the important question
of whether PR affects cardiovascular risk in COPD.
Vivodtzev conducted a study in 2010 to investigate
whether exercise training decreased arterial stiffness in
patients with COPD. The randomized trial of aerobic
endurance training was run for four weeks in 17 stable
patients with moderate to severe COPD free from dia-
betes and respiratory exacerbation within the preceding
three months. The participants were divided into two
groups; a trained group (n = 10) and an untrained group
(n = 7). Arterial stiffness was measured blindly by re-
cording the carotid-radial pulse wave velocity (c-r
PWV). The baseline measurements of c-r PWV were
similar in both groups. After four weeks of an aerobic
endurance training programme, c-r PWV readings were
stable in the untrained group and significantly reduced
in the trained group (from 10.3 ± 0.7 to 9.2 ± 0.8 m/s,
P = 0.001). c-r PWV reduction correlated with improve-
ments in walking distance (r = 0.49), systolic blood pres-
sure (r = 0.79), muscle endurance (r = 0.48), and fasting
glucose (r = 0.59) in all patients (P = < 0.05), and with
changes in maximal heart rate and oxygen consumption
(r = 0.70, P = 0.02) in trained patients. The authors con-
cluded that arterial stiffness appears to be improved fol-
lowing exercise in stable patients with COPD.
Gale conducted a study in 2011 to investigate if pul-
monary rehabilitation affected cardiovascular risk factors
in patients with COPD. The study was run for seven
weeks in the context of a multidisciplinary pulmonary
rehabilitation programme on a total of 32 stable COPD
participants who were free from ischemic heart disease,
cardiac failure, diabetes mellitus or malignancy. These
32 participants were compared with 20 healthy controls
at the baseline assessment. In all subjects, aortic pulse
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wave velocity was measured before the programme and
repeated for those who completed PR. On the initial
measurements of aortic stiffness, aPWV was increased
in patients compared to the control group (p < 0.05).
After seven weeks of the multidisciplinary pulmonary re-
habilitation programme, 22 patients completed the
programme. aPWV was re-measured for those who
completed the programme, and was significantly reduced
in comparison to the baseline measurement (from
9.8 ± 3.0 m/s to 9.3 ± 2.7 m/s, p = ≤ 0.05). Gale concluded
that cardiovascular risk measured by aortic stiffness was
significantly improved following multidisciplinary pul-
monary rehabilitation in patients with COPD.
Vanfleteren conducted a study in 2014 that aimed to
confirm increased arterial stiffness in COPD, evaluate its
relationship with systemic inflammation and, most im-
portantly, to examine if the increased arterial stiffness
was influenced by PR. The study was run for two years
on a total of 168 healthy control participants who had
normal pulmonary function tests and 162 COPD pa-
tients. Among the COPD group, only 129 patients com-
pleted the PR programme and were re-assessed. It was
reported that arterial stiffness was increased in COPD
patients at baseline measurement compared to controls.
Furthermore, it was reported that systemic inflammatory
markers were not related to increased arterial stiffness in
COPD. Overall, there was no change in aPWV measure-
ment after PR (10.7 ± 2.7 versus 10.9 ± 2.5 ms, p = 0.339).
The Authors concluded that changes in arterial stiffness
in COPD were not related to markers of systemic inflam-
mation and not influenced by pulmonary rehabilitation.
We noted heterogeneity across the included studies re-
garding exercise intensity and programme duration (and
such heterogeneity prevented meta-analysis). In the Gale
study [6], arterial stiffness significantly improved after PR.
Additionally, there was a significant reduction in central
mean arterial pressure (103 ± 14 to 95 ± 14 mmHg;
p = <0.001) which may account for the reduction in
aPWV. The larger negative study by Vanfleteren [7] was
well designed consisting of 40 sessions, twice as many as
Gale [6]. There was no effect on reduction of aPWV or on
mean arterial pressure. The Vivodtzev study did not in-
clude an education component [5].
The available data on the ability of PR to reduce car-
diovascular risk in COPD therefore remains contra-
dictory. Importantly, we noted that CV responses to
Fig. 1 PRISMA Flow Diagram
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PR appeared highly heterogeneous in the Vanfleteren
paper [7]. This raises the important hypothesis that
some patients may benefit and that some patients may
be at increased risk from PR in COPD (Fig. 2, derived
from the original paper [7]. This may be clinically
important.
Cardiovascular co-morbidity is common in COPD.
Chen conducted a systemic review and meta-analysis
aiming to quantify the magnitude of the association be-
tween COPD and increased prevalence of cardiovascular
risk-factors and co-morbidity [15]. Twenty seven obser-
vational studies were included in the meta-analysis. The
pooled odds of cardiovascular disease was higher in sub-
jects with COPD compared to people without (meta-
odds ratio OR 2.46, 95% CI 2,02–3.00; p < 0.0001). This
comprised a two to five-fold higher risk of major cardio-
vascular disease sub-types (ischemic heart disease, cardiac
dysrhythmia, heart failure, diseases of the pulmonary cir-
culation and arterial diseases), and a one-third increased
risk of hypertension and diabetes. No significant increased
risk of cerebrovascular disease, dyslipidaemia, and obesity
was detected in patients with COPD.
The papers examined in this systematic review in-
cluded information on baseline cardiovascular risk. In
the Vanfleteren paper, among 162 COPD patients there
was no statically significant difference in aPWV after PR
(p = 0.339) despite the prevalence of recorded cardiac
comorbidities including myocardial infraction (n = 16
[9.9%]), heart failure (n = 5 [3.1%]), peripheral arterial
diseases (n = 30 [18.5%]), cerebrovascular disease
(n = 14 [8.6%]), diabetes (n = 7 [4.3%]) or any other car-
diovascular diseases (n = 50 [30.9%]). Furthermore, even
after subdividing the patients into subgroups based on
cardiovascular risk factors including smoking (ever
smoked), hypertension, hyperlipidemia, age and obesity
there was no notable difference in response (p > 0.05).
In the positive studies, Vivodtzev reported that none of
the participants had a history of ischemic heart disease
or stroke. They reported that the significant reduction
in PWV correlated with systolic BP (r = 0.79) and
fasting glucose (r = 0.59). In the Gale study, none of
the participants had reported cardiovascular disease.
However, PR did improve some cardiovascular risk fac-
tors, including both blood pressure and cholesterol
(p = <0.05).
None of the three included studies in this review re-
ported data on subsequent risk of hospital admission or
mortality following the exercise programme. Puhan con-
ducted a systematic review aiming to compare the effect
of PR after COPD exacerbation in reducing hospital ad-
mission and mortality [16]. Twenty RCTs (1477 partici-
pants) were included in this review. Eight studies
including 810 participants contributed data on hospital
readmission indicating that PR reduced hospital re-
admission (pooled odds ratio (OR) 0.44, CI 0.21 to 0.91)
but the results were heterogeneous (77%). Six studies
contributed data on mortality. The duration of follow-up
period ranged from 3 to 48 months with one study
showing reduced mortality and four no effect. The
quality of evidence was low. None of the trials considered
mortality as a primary outcome and the analysis did not
show a statistically significant influence of PR on mortality
(OR = 0.68, CI 0.28 to 1.67) with significant heterogeneity
reported across the studies.
It can be seen from the analysis above that CVD and
CVRs are very prevalence among COPD patients, which
might be expected to proportionally influence the
aPWV. Therefore, the variety of the included patients in
terms of CVDs and CVRs might also count to explain
the current results’ heterogeneity of this systematic
review.
The available data on the ability of PR to reduce car-
diovascular risk assessed by aPWV in COPD therefore
remains contradictory. Interestingly, Oliveira performed
a systemic review with the aim of examining the effect
of exercise training on arterial stiffness in Coronary
Artery Disease (CAD) patients assessed by measuring ar-
terial stiffness or related indexes (eg. indexes of wave









Gale 2011 [6] 3 2 3 3 3 3 3
Vanfleteren 2014 [7] 3 3 3 3 3 3 3
0 = Definitely no (therefore high risk of bias), 1 = Mostly no, 2 = Mostly yes, 3 = Definitely yes (therefore low risk of bias)
Table 3 Risk of bias in the included randomised trial














Vivodtzev 2010 [5] Unclear Unclear Unclear Low Low Unclear Low
Low: Low risk of bias, High: High risk of bias, Unclear: Unclear risk of bias
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reflection or arterial compliance) [17]. Five studies were
included in this review with a total of 271 participants
varying in age (48–67 years) and exercise programme
duration (6 to 20 weeks). Participants were diagnosed
with CAD after an acute myocardial infarction, coronary
artery bypass graft or coronary angioplasty. Overall,
Oliveira found that exercise programs in CAD patients
led to improved outcome measures. Specifically, there
was a significant reduction in PWV despite use of differ-
ent measurement methods including brachial-ankle PWV
(reduction of 0.120 m/s), carotid-femoral PWV (4.1 m/s
to −0.7 m/s) and carotid-radial PWV(0.7 m/s). The au-
thors reported a greater reduction in PWV in CAD pa-
tients who completed a 20-week (−1.0 ± 0.3 m/s) versus a
12-week training course (−0.6 ± 0.2 m/s).
In summary, we are unable to conclude whether
there is or is not a significant change in aortic pulse-
wave velocity in response to PR in COPD. Therefore
further work is required to definitively address this
question and in particular whether there may be sub-
groups of patients who do and do not respond. There
is an urgent unmet need for evidence-based standar-
dised interventions that reduce the risk of cardiovascu-
lar events in patients with COPD. Conducting further
studies considering confounding variables such as car-
diovascular risk factors and disease, medication, exer-
cise intensity and duration of the programme may
better assess the benefits of PR programme on CV risk
in COPD.
Strength and limitations
The strength of this work is that there is no previous
systematic review on the effect of PR on CV risk in
COPD measuring aPWV. A potential limitation of this
report was that we excluded non-English studies.
Conclusion
We have systematically searched for and reported those
studies that evaluated the effect of PR on CV outcomes
in COPD. There is some existing data evaluating the
effect of PR on cardiovascular risk in COPD, with one
(larger and higher quality) negative study and two
smaller positive ones. Study heterogeneity results in con-
tinuing controversy in the field. The negative study also
reported inter-patient heterogeneity in responses that
are unexplained, require further evaluation and may be
clinically important. Results generated from this report
will be of importance for researchers interested in asses-
sing the benefits of PR on reducing CV risk in COPD.
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